Luye Group 
Welcome,         Profile    Billing    Logout  
 36 Products   29 Diseases   36 Products   123 Trials   3033 News 


12345678910111213...3334»
  • ||||||||||  goserelin acetate 3-month extended-release microspheres (LY01022) / Luye Group
    Review, Journal:  An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management. (Pubmed Central) -  Aug 28, 2024   
    With the recent approval of goserelin 10.8 mg LA by Health Canada on 6 May 2024, for use in breast cancer, Canada is the latest to join over 60 countries worldwide to expand the accepted indications for goserelin LA and ensure its availability to potentially enhance healthcare delivery, patient care, and breast cancer outcomes. Goserelin LA offers premenopausal patients a means to more effectively manage the constraints imposed by breast cancer treatment and its impact on survivorship.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Review, Journal, IO biomarker:  Lost at SCLC: a review of potential platinum sensitizers. (Pubmed Central) -  Aug 23, 2024   
    By extension, lost at SCLC references the current confusion about how to circumvent the chemoresistance, particularly platinum resistance, which so plagues the treatment of extensive-stage small cell lung cancer (ES-SCLC) that in 2012 the US National Cancer Institute (NCI) designated it a "recalcitrant cancer." Over a decade later, despite the approval of immune checkpoint inhibitors and the conditional approval of lurbinectedin, the prognosis for ES-SCLC, and especially platinum-resistant ES-SCLC, has scarcely improved. The focus of this review, which briefly summarizes current treatment options for ES-SCLC, is on five clinical-stage therapies with the potential to successfully reverse the platinum resistance that is perhaps the biggest obstacle to better clinical outcomes.
  • ||||||||||  temozolomide / Generic mfg.
    Review, Journal:  Challenges and future perspectives for the use of temozolomide in the treatment of SCLC. (Pubmed Central) -  Aug 17, 2024   
    Several studies have revealed the synergistic activity of temozolomide with poly-ADP-ribose polymerase (PARP) inhibitors, that prevent repair of TMZ-induced DNA damage. This review focuses on the rationale for the use of TMZ in ES-SCLC and provides an overview of the main trials that have evaluated and are currently investigating its role, both as a single-agent and in combinations, in relapse or refractory disease.
  • ||||||||||  Pozenveo (poziotinib) / Assertio, Exkivity (mobocertinib) / Takeda, Rybrevant (amivantamab-vmjw) / J&J
    Journal, EGFR exon 20:  Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer. (Pubmed Central) -  Aug 10, 2024   
    Further proteomics and genomics work is needed to define additional response biomarkers. Our study revealed EGFR-dependent and -independent mechanisms of mobocertinib resistance in patients with advanced EGFR Ex20ins-mutant NSCLC.
  • ||||||||||  Calsed (amrubicin) / BMS, Nippon Kayaku, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Chemotherapy Sensitivity for Recurrent Small-Cell Lung Cancer Based on Chemotherapy-Free Interval and Treatment Regimens (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2228;    
    The concept of sensitive relapse was established before the advent of amrubicin (available in Japan) and lurbinectedin (recommended in ESMO and NCCN guidelines), which are effective for recurrent SCLC...Thirty-four were treated by platinum-doublet re-challenge, and 29 received monotherapy of amrubicin, topotecan, or irinotecan...It is still unclear whether the response of second-line chemotherapy following ICI is elevated compared to conventional chemotherapy. Further investigation is needed.
  • ||||||||||  Lipusu (liposomal paclitaxel) / Luye Group
    Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Treatment-Naive Patients with Advanced Lung Squamous Cancer (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1517;    
    P3, P4
    Methods : This post-hoc analyses were performed in two independently conducted trials: Camel-Seq (NCT03668496) (Cohort A) and LIPUSU (NCT02996214) (Cohort B)...More importantly, MinerVa-Delta is able to accurately identify SD patients, a heterogeneous patient population in clinic, who can benefit from the initial treatment. This makes it a valuable supplement to the current image-based RECIST classification system.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Modulation of EMT Increases the Activity of Lurbinectedin in Small Cell Lung Cancer (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1490;    
    This makes it a valuable supplement to the current image-based RECIST classification system. Their sensitivity to cisplatin and etoposide (chemotherapeutic drugs), as well as lurbinectedin alone and combination with capmatinib (MET inhibitor), was tested using the Cell Titer-Glo
  • ||||||||||  Lipusu (liposomal paclitaxel) / Luye Group
    Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Treatment-Naive Patients with Advanced Lung Squamous Cancer (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1268;    
    P3, P4
    Methods : This post-hoc analyses were performed in two independently conducted trials: Camel-Seq (NCT03668496) (Cohort A) and LIPUSU (NCT02996214) (Cohort B)...More importantly, MinerVa-Delta is able to accurately identify SD patients, a heterogeneous patient population in clinic, who can benefit from the initial treatment. This makes it a valuable supplement to the current image-based RECIST classification system.
  • ||||||||||  ABBV-706 / AbbVie, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1197;    
    P1
    Although the sample size was small and the study was limited to a single site, these data support SEZ6 as a potential ADC-targetable biomarker in SCLC. This real-world SCLC cohort could also be used as a borrowed control for the phase 1 single-arm study being conducted in patients with SCLC treated with ABBV-706 to help identify novel predictive biomarkers and interpret the outcomes from the study.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Teriflunomide in Vitro or Leflunomide in Vivo Treatment Increases the Efficacy of Lurbinectedin in SCLC (30A) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1106;    
    Conclusions : Collectively, our data suggest combinations of Lurbinectedin with Teriflunomide or Leflunomide are a potential therapeutic approach to suppress SCLC progression. These novel results pave the way for clinical trials in the future to validate these treatment strategies in patients with SCLC.
  • ||||||||||  teriflunomide / Generic mfg., leflunomide / Generic mfg.
    Journal:  Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC. (Pubmed Central) -  Jul 12, 2024   
    Additionally, lurbinectedin (Lur) and Teri potently and synergistically inhibited spheroid growth and depleted uridine and DRP1 phosphorylation in mouse tumors. Our results suggest combinations of Carbo and Lur with Teri or Leflu are efficacious and underscore how the relationship between DRP1/DHODH and mitochondrial plasticity serves as a potential therapeutic target to validate these treatment strategies in SCLC clinical trials.
  • ||||||||||  goserelin acetate / Generic mfg.
    Journal:  GOSERELIN INHIBITING UPTAKE ON SODIUM PERTECHNETATE Tc-99M THYROID SCAN: A CASE REPORT. (Pubmed Central) -  Jun 28, 2024   
    This case report highlights a rare instance of a middle-aged woman with symptomatic toxic goitre whose sodium pertechnetate Tc-99m thyroid scan uptake was inhibited by goserelin therapy. Medical personnel caring for patients on goserelin need to be aware of the possibility of it affecting thyroid function.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal, Tumor mutational burden, PD(L)-1 Biomarker:  Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. (Pubmed Central) -  Jun 26, 2024   
    A repeat biopsy following the development of lurbinectedin resistance showed a new actionable ERBB2 alteration without significant change in the tumor mutation burden (six mutations/Mb). The present report suggests that lurbinectedin may be active and should be further explored in SCBC harboring TP53 mutations and amplifications in E2F3 and MYC family complexes.
  • ||||||||||  Krazati (adagrasib) / BMS, Pozenveo (poziotinib) / Assertio, Lumakras (sotorasib) / Amgen
    Pan-HER Inhibition Overcomes Feedback Adaptation Resistance to KRAS G12C Inhibition in KRAS G12C Mutant Non-Small Cell Lung Cancer (Grace Murray Hopper Auditorium, Yale West Campus Conference Center) -  Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_66;    
    KRAS G12C inhibitors sotorasib and adagrasib are FDA approved for advanced/metastatic KRAS G12C-positive NSCLC, although the duration of benefit from these drugs is relatively modest and therapeutic resistance typically emerges relatively quickly to these drugs...We observed that in combination with KRAS G12C inhibitors pan-HER TKIs such as poziotinib yielded a synergistic effect compared to HER2 TKI treatment...The combination of pan-HER TKIs with KRAS G12C inhibitor suppressed tumor growth significantly as compared to KRAS G12C inhibitor alone with a tolerable toxicity profile in KRAS G12C mutant patients derived xenograft models. Collectively, our findings indicate that the adaptive feedback activation of HER family members, including not only EGFR but also HER2 and HER3, diminishes the efficacy of KRAS G12C inhibitors against KRAS G12C-positive NSCLC tumor cells, and that the combination of pan-HER TKIs with KRAS G12C inhibitors may be more effective than KRAS G12C inhibitors alone.
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Trastuzumab Deruxtecan Resistance can be Mediated by Payload Resistance or Secondary Extracellular ERBB2 Mutations but Sensitivity to HER2 Tyrosine Kinase Inhibitors is Maintained (Grace Murray Hopper Auditorium, Yale West Campus Conference Center) -  Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_65;    
    T-DXd resistant cell lines were sensitive to payloads with alternate mechanisms of action including maytansine and likewise retained sensitivity to the HER2 ADC trastuzumab emtansine (T-DM1) which utilizes DM1 as a payload...T-DXd resistant cells remained highly sensitive to HER2 TKIs including poziotinib, afatinib, and zongertinib...Moreover, resistance to trastuzumab-based ADCs can also be mediated by secondary mutations within domain IV of HER2 or loss of the extracellular terminal of HER2. However, these alterations do not diminish HER2 TKI activity.
  • ||||||||||  Review, Journal, EGFR exon 20:  Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer. (Pubmed Central) -  Jun 19, 2024   
    Despite these advances, challenges in overcoming resistance mutations and improving central nervous system penetration remain. Future research should focus on optimizing first-line combination therapies and enhancing diagnostic strategies for comprehensive mutation profiling.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Journal:  Evolution of a Synthetic Strategy toward the Syntheses of Bis-tetrahydroisoquinoline Alkaloids. (Pubmed Central) -  Jun 14, 2024   
    ConspectusThe bis-tetrahydroisoquinoline (bis-THIQ) natural products represent a medicinally important class of isoquinoline alkaloids that exhibit broad biological activities with particularly potent antitumor properties, as exemplified by the two U.S. FDA approved molecules trabectidin and lurbinectedin...Finally, we include our unsuccessful late-stage oxygenation attempts prior to the discovery of the Pd-catalyzed C-O cross-coupling reaction. With this full disclosure of the chemistry developed for the syntheses of bis-THIQs, we hope our orthogonal synthetic tactics will provide useful information and serve as an inspiration for the future development of bis-THIQ pharmaceuticals.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  LURBIMUNE: Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (clinicaltrials.gov) -  Jun 4, 2024   
    P2,  N=0, Withdrawn, 
    Our findings show that quercetin/lurbinectedin-loaded GO NPs may be a promising lung cancer treatment, opening new avenues for targeted and effective therapies. N=82 --> 0 | Trial completion date: Apr 2026 --> May 2024 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2024 --> May 2024
  • ||||||||||  Pozenveo (poziotinib) / Assertio
    Trial completion date, Trial primary completion date, EGFR exon 20, HER2 exon 20, Metastases:  NCI-2017-00831: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (clinicaltrials.gov) -  May 23, 2024   
    P2,  N=93, Active, not recruiting, 
    For patients with PRrOC who have exhausted treatment options, nivolumab and mirvetuximab may be considered as alternatives because of their better safety profiles. Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2025
  • ||||||||||  Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
    PET/CT Study of Dopamine Transporter (DAT) Binding with the Novel Triple Reuptake Inhibitor Toludesvenlafaxine in Rats and Humans (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_229;    
    These results represent the first to confirm the binding of toludesvenlafaxine to DAT in both rats and humans using PET/CT, and its elevation of brain DA level, which may help understand the unique pharmacological and functional effects of triple reuptake inhibitors such as toludesvenlafaxine. Learning Objectives PoM exploratory clinical research by combining PET/CT and microdialysis; to assess Dopamine Transporter occupancy in the Healthy Adult Brain Using 11C-CFT PET
  • ||||||||||  BA1202 / Luye Group
    Enrollment open, Metastases:  A Study of BA1202 in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 25, 2024   
    P1,  N=78, Recruiting, 
    Hence, to avoid LRB overexposure when co-administered with strong CYP3A4 inhibitors, an LRB dose reduction proportional to CL reduction should be applied. Not yet recruiting --> Recruiting